This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Analysts' Actions: CBRL CHK DE EA EBAY

PDC Energy (PDCE) was downgraded at Stifel Nicolaus to hold from buy. Company cut its production data, Stifel said. Stock also cut from the Select List.

Patterson (PDCO) was upgraded at UBS to buy from neutral. As a North American pure-play, the company will benefit most from increasing demand in the region, UBS said. Price target is $43.

Sarepta (SRPT) was initiated with a buy rating at Deutsche Bank. $45 price target. Muscular dystrophy can drive growth over the next several quarters, Deutsche said.

Stifel Nicolaus (SF) was downgraded to hold at TheStreet Ratings.

Unum Group (UNM) was downgraded at Bank of America/Merrill Lynch to neutral from buy. $29 price target. Best-performing life insurer year to date, BofA/Merrill said.

STOCK COMMENTS/EPS CHANGES

Citigroup (C) price target was raised at Deutsche Bank. Shares are now seen reaching $53. Company can continue to exceed sales expectations and move to $6 a share of earnings in 2015, Citi said. Buy rating.

lululemon athletica (LULU) price target and estimates were reduced at UBS. Earnings estimates were cut after the company had to recall its Luon pants due to quality issues, said UBS. New price target is $77.

Nike (NKE) estimates were reduced at UBS due to foreign exchange rates. The company reports earnings on Thursday.

Norfolk Southern (NSC) price target and estimates were increased at Cowen. Intermodal and crude oil are driving better-than-expected traffic and operational metrics, Cowen said. Price target is $85.

Onyx Pharmaceuticals (ONXX) price target and estimates were increased after a front-line Kyprolis survey showed robust uptake, said Jefferies. Price target is now $104.

Proactive Life (PL) price target was increased at UBS to $39. Solid BVPS growth will drive stock upside, UBS said.

Toronto-Dominion Bank (TD) was downgraded to hold at TheStreet Ratings.

Vertex Pharmaceuticals (VRTX) price target and estimates were increased at J.P. Morgan. Changes made after speaking with physicians about the cystic fibrosis trial that is set to launch, said J.P. Morgan. Price target is now $86.

Valeant (VRX) estimates were increased at UBS. Aggressive M&A is expected after meeting with management, UBS said.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:






Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs